2019 Articles

Volume 1 Issue 1

LSD: A Comprehensive Review

Gershom Hernandez, M.D.

Volume 1 Issue 1

Abstract:

Objective: This paper aims to compile the history, available data, pharmacology, notable studies, current neuroimaging studies, and psychology of Lysergic acid diethylamide (LSD) in order to assess any potential medical utility. Methods: Literature Review Discussion: While promising, notable studies do not provide significant evidence for clinical use. However, the evidence is compelling enough that more research and knowledge is warranted.

Introspective Acceptance of Gender Identity: Case Report Detailing Resolution of Gender Dysphoria After Use of LSD

Joseph Pullara, M.D.

Volume 1 Issue 1

Abstract:

Gender dysphoria is a rare psychiatric disorder that has traditionally been managed and treated using hormone replacement and intensive plastic surgery. Most psychiatric medications and therapies offer little benefit in regards to the symptoms of gender dysphoria and instead are initiated to treat associated conditions such as anxiety or depressive disorders. This report describes the case of a 32-year-old male patient with a long-standing history of Gender Dysphoria (GD) who had symptoms almost completely resolve after orally ingesting 300 micrograms of Lysergic Acid Diethylamide (LSD). This case serves to provide evidence in support of LSD as an effective psychotherapeutic treatment modality.

Psychedelic Assisted Psychotherapy for the Treatment of Gender Dysphoria

Tyler Kjorvestad, M.D.

Volume 1 Issue 1

Editorial

Psilocybin Use in the Future Psychiatric Practice: A Comprehensive Review

Anthony Ceman, M.D.

Volume 1 Issue 1

Abstract:

Objective: Psilocybin, the psychoactive compound found in “magic mushrooms,” is currently a Schedule I substance; as such, the United States Federal Drug Administration consider it to have a high potential for abuse and no medical benefit. However, recent research using psilocybin for the treatment of psychiatric disorders has shown that in certain conditions, it may have superior efficacy with fewer adverse effects than current psychotherapeutic agents. A review of the literature was conducted to elucidate the benefits of psilocybin further and explore the possible implication of future clinical use. Search Methods: Pubmed search terms: psilocybin and depression, anxiety, alcohol, alcohol cessation, and mechanism of action, which resulted in 187 articles with 22 being selected for review. Results: Severe studies with smaller sample studies have shown positive results in the use of psilocybin in treatment-resistant depression, anxiety and depression associated with advanced-stage cancer, along with alcohol and tobacco use disorders. Limited, but positive data show possible treatment use in OCD and anxiety disorders.​

Beyond Vaping: Psilocybin for the Treatment of Tobacco Use Disorder

Tyler Kjorvestad, M.D.

Volume 1 Issue 1

Editorial

Ayahuasca and Treatment of Post-Traumatic Stress Disorder: A Case Report

Anthony Ceman, M.D.

Volume 1 Issue 1

Abstract:

Post-traumatic stress disorder (PTSD) is a psychiatric disorder that affects about 8% of the population in the United States. Conventional treatments for PTSD are a category of medications commonly referred to as antidepressants (selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors) along with psychotherapy. Only two of these medications have received Federal Drug Administration (FDA) approval for PTSD treatment, Sertraline, and Paroxetine2. Current evidence is emerging for the treatment of PTSD symptoms with psychedelic substances, one of which is 3,4-Methylenedioxymethamphetamin (MDMA), with it recently receiving a breakthrough therapy designation from the FDA2. This report describes the case of a male United States military veteran who suffers from PTSD symptoms related to both military experiences and childhood trauma and had resolution of those symptoms after administration of Ayahuasca every 6 months under the guidance of a Shaman in Peru. This case serves to provide evidence for the use of Ayahuasca in the treatment of PTSD.

  • Facebook Social Icon
  • Instagram

©2019 by The Journal of Psychedelic Psychiatry. Proudly created with Wix.com